Liver Enzyme Requirements for Starting Terbinafine
Terbinafine, an antifungal used for conditions like onychomycosis and tinea infections, requires baseline liver function tests (LFTs) before initiation due to rare but serious risks of hepatotoxicity. Guidelines recommend checking alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin levels.[1][2]
Normal baseline values typically include:
- ALT: <40-50 U/L (lab-specific upper limit of normal, ULN)
- AST: <40-50 U/L
- ALP: <115-130 U/L
- Total bilirubin: <1.2 mg/dL
Terbinafine is contraindicated if any LFT exceeds 2x ULN at baseline, as elevated enzymes indicate potential preexisting liver impairment. Some clinicians withhold therapy if levels are >1.5x ULN or if there's active liver disease, alcohol abuse, or other risk factors.[1][3]
Why Test Liver Enzymes Before Starting?
Hepatotoxicity occurs in about 1 in 50,000-120,000 patients, with symptoms like jaundice or fatigue appearing 4-6 weeks into therapy. Pretesting identifies at-risk patients and establishes a reference for monitoring.[2][4]
What Happens if Enzymes Are Elevated?
- Mild elevation (<2x ULN): May proceed with close monitoring (LFTs at 4-6 weeks), but many providers delay or choose alternatives.
- >2x ULN: Do not start; investigate cause first.
- During therapy: Stop immediately if enzymes rise >2x ULN or symptoms appear.[1][3]
Monitoring Schedule After Starting
Repeat LFTs at 4-6 weeks, then periodically if risk factors exist. No routine testing beyond 6 weeks for low-risk patients unless symptoms develop.[2]
Who Should Avoid Terbinafine Entirely?
Contraindicated in active/chronic liver disease, recent heavy alcohol use, or hypersensitivity. Use caution in elderly patients or those on hepatotoxic drugs (e.g., statins).[1][4]
Alternatives if Liver Enzymes Are High
Options include itraconazole (similar LFT requirements), fluconazole, or topical antifungals for milder cases. Pulse dosing may reduce systemic exposure in some regimens.[3]
[1]: FDA Label - Lamisil (terbinafine)
[2]: American Academy of Dermatology Guidelines
[3]: UpToDate - Terbinafine
[4]: British National Formulary (BNF)